Progyny jumps on higher FY22 forecast
28/11/2022 13:54
** Fertility benefits management company Progyny Inc's
shares PGNY.O up 4% premarket at $35.80 after co raised FY22
forecast for revenue and net income
** Sees FY22 sales between $781.5 mln and $786.5 mln vs
previously estimated range of $775 mln to $785 mln
** PGNY says updated guidance reflects resumption of
deliveries of fertility medication Menopur, which was previously
facing a shortage
** Co sees historical dispensing patterns to resume by the
end of 2022
** All seven brokerages covering the stock rate it "buy" or
higher; median PT is $55 - Refinitiv
** Up to Friday's close, stock had fallen 32% vs a 18%
decline in the S&P 400 healthcare index .SPMDCA
(Reporting by Johann M Cherian in Bengaluru)
((johann.mcherian@thomsonreuters.com;))